In 2015, multinational pharmaceutical companies have shown competition in the asthma and COPD treatments

Since the beginning of the New Year, multinational pharmaceutical companies have shown high interests in asthma and COPD (Chronic Obstructive Pulmonary Disease) treatments.

As the number of asthma and chronic obstructive pulmonary disease patients increases, multinational pharmaceutical companies are planning to develop asthma and COPD treatments.

First, BoehringerIngelheim has announced the ...